MNTA's share price climbed because they helped the FDA determine what the problem was with heparin.
Yes, it is important that the heparin supply is safe, but the FDA has limited resources to monitor everything manufactured overseas.
The FDA cannot possibly oversee all oversea manufacturing facilities, including those in China, where the government expressly disavows the need to monitor products produced for export.
MNTA should avoid acting as a surrogate regulatory entity overseeing product purity of biologics whose manufacture and true QA they have no control over, lest they set a large red bulls eye over their corporate logo with the phrase, "SUE ME' writ large.
Market Data 
Markets 
AI
